FMN2

FMN2 is a formin-family actin nucleator that couples cytoskeletal remodeling to cell-cycle control, nuclear protection, and neuronal architecture (PMID:23375502, PMID:23839046, PMID:27839864). In the cell-cycle arm, FMN2 is transcriptionally induced upon p14ARF activation through an NF-κB-dependent relief of RelA/E2F1 repression at its promoter, independently of p53; its N-terminus then stabilizes the CDK inhibitor p21 against degradation to enforce cell-cycle arrest (PMID:23375502, PMID:23839046). In the cytoskeletal arm, FMN2 builds a dedicated perinuclear actin/focal-adhesion system that governs nuclear shape and positioning and limits nuclear-envelope rupture and DNA double-strand breaks during confined migration, thereby supporting cell survival and metastasis (PMID:27839864). The same actin-nucleating activity underlies neuronal roles: FMN2 localizes to dendritic punctae and is required for dendritic spine formation (PMID:25480035), and in growth cones it functions as a molecular clutch coupling actin to the substrate to generate the traction forces needed for motility (PMID:33002558). FMN2 expression is constrained post-transcriptionally by miR-144 binding to its 3′UTR, with consequences for proliferation and cell-cycle arrest (PMID:27556228).

1. 2010 Medium

   Established a link between FMN2 and transformation by showing its overexpression drives anchorage-independent growth alongside actin cytoskeleton disruption, framing FMN2 as an actin-regulating factor with oncogenic potential.

   Evidence Soft agar colony formation and actin/morphology staining upon mouse Fmn2 overexpression

   PMID:21135260

   Open questions at the time

   • Mechanism connecting actin disruption to transformation not defined
   • No endogenous loss-of-function counterpart
   • Single overexpression system
2. 2013 High

   Resolved how FMN2 enters cell-cycle control by placing it downstream of p14ARF/NF-κB signaling and identifying its N-terminus as the determinant that stabilizes p21 to enforce arrest, independently of p53.

   Evidence SILAC proteomics, ChIP of RelA/E2F1 at the FMN2 promoter, NF-κB inhibition, p21 stability and domain-mutagenesis assays

   PMID:23375502 PMID:23839046

   Open questions at the time

   • Biochemical mechanism by which the N-terminus protects p21 from degradation unresolved
   • Whether actin-nucleation activity is required for p21 stabilization untested
3. 2014 Medium

   Connected FMN2-mediated actin nucleation to neuronal connectivity by localizing it to dendritic punctae and showing spine density falls in Fmn2-knockout mice and patient-derived neural cells.

   Evidence Immunofluorescence localization, mouse germline knockout spine-density phenotyping, iPSC-derived neural cell synaptic density

   PMID:25480035

   Open questions at the time

   • Molecular partners at dendritic punctae not identified
   • Causal nucleation mechanism for spine formation not directly demonstrated
4. 2016 High

   Defined a distinct cytoskeletal function: FMN2 generates a perinuclear actin/focal-adhesion system that controls nuclear shape and shields the nucleus from envelope rupture and DNA damage during confined migration, promoting survival and metastasis.

   Evidence Live-cell imaging of the perinuclear structure, knockdown/knockout with γH2AX and envelope-rupture reporters, mouse melanoma extravasation/metastasis assay

   PMID:27839864

   Open questions at the time

   • How FMN2 is targeted to the perinuclear region unknown
   • Relationship between this structure and the p21/cell-cycle role unexplored
5. 2017 Medium

   Showed FMN2 is post-transcriptionally regulated by miR-144 via direct 3′UTR binding, with FMN2 overexpression rescuing miR-144's anti-proliferative and cell-cycle-arrest effects in leukemia cells.

   Evidence Dual-luciferase 3′UTR reporter, qRT-PCR, western blot, FMN2 rescue, in vivo xenograft

   PMID:27556228

   Open questions at the time

   • Whether miR-144 regulation operates outside leukemia untested
   • Downstream effectors of the rescue not dissected
6. 2020 Medium

   Provided a mechanistic basis for FMN2 in axon guidance by demonstrating it stabilizes growth-cone point contacts and acts as a molecular clutch coupling actin flow to the substrate to generate traction.

   Evidence F-actin retrograde flow analysis, traction force microscopy, point-contact component analysis, knockdown with traction-stress quantification

   PMID:33002558

   Open questions at the time

   • Direct binding partners linking FMN2 to adhesion complexes not identified
   • Single lab and model system
7. 2022 Low

   Extended FMN2's DNA-damage/p21 axis to oocytes by associating a missense variant with reduced FMN2 and p21, elevated γH2AX, and increased chromosomal breakage in premature ovarian insufficiency patient cells.

   Evidence Western blot of FMN2/p21/H2AX and chromosomal breakage analysis in patient versus control cells

   PMID:35227295

   Open questions at the time

   • Single patient case with limited controls and no functional rescue
   • Causality of the variant not established
   • Tissue-specific mechanism in oocytes undefined

• It remains unresolved whether FMN2's actin-nucleation activity, p21 stabilization, and perinuclear/genome-protective functions are mechanistically linked or represent separable activities of the same protein.
• No structure-function study tying nucleation activity to p21 stabilization
• Direct molecular partners of FMN2 largely uncharacterized